Receive the latest updates from Matrix Medical in real time to understand product information.

On April 29, 2025, the "Hangzhou Taikun Biomedical Industry Finance Summit" hosted by Tailong Investment was held in Hangzhou. As a professional equity investment management institution in the field of biomedicine, Tailong Investment relies on a 20 billion yuan fund management scale and forward-looking strategic layout to build a high-end dialogue platform for industry finance integration. Hangzhou Matrix Medical Technology Co., Ltd. (hereinafter referred to as "Matrix Medical") has made a heavyweight debut with multiple innovative products. With its profound accumulation and forward-looking layout in the field of vascular intervention, it is exploring the forefront of the industry with top global enterprises, research institutions, and investment institutions.

Technological barriers: Innovative products win capital attention

As a domestic innovation representative in the field of high-value consumables for vascular intervention, Matrix Medical has made its debut in the capital circle with three major product lines: neural intervention, cardiovascular intervention, and peripheral vascular intervention. Faced with the transformation of medical device investment logic under the normalization of centralized procurement, Matrix Medical has become one of the most attention grabbing medical device companies at the summit with its innovative concept of "natural vascular stent".

Breakthrough of domestic innovators in the "golden track" of vascular intervention

During the summit, the booth of Matrix Medical attracted many attendees to stop and inquire. The company team has had in-depth discussions with multiple investment institutions and partners to explore cooperation opportunities through technical analysis, clinical data display, and market trend analysis. The innovative strength and market potential of Juzheng Medical have been highly recognized by the industry, injecting new impetus into future development.

Dr. Ji Peihong, founder of Matrix Medical, said, "Thank you to Tailong Investment for building this platform, which gives us the opportunity to have in-depth exchanges with top companies and investment institutions in the industry, and showcase our latest research and development achievements. In the future, we will continue to focus on the field of vascular intervention, increase research and development investment, launch more innovative products, and provide patients with safer and more effective 'domestic alternative' treatment solutions

Institution Introduction - Tailong Investment

Tailong Investment was established in 2021 and is a professional equity investment management institution specializing in the fields of biomedicine, medical devices, and big health. Its fund management scale is 20 billion yuan. Tailong Investment has a professional and experienced investment team, focusing on biopharmaceuticals, innovative medical devices, CXO core services and innovative fields, and excellent biopharmaceutical industry funds. We are committed to building a biopharmaceutical industry value investment platform that is loyal to science and cross cycle.